Baxter Change in Accounts Receivable 2010-2025 | BAX
Baxter annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Baxter change in accounts receivable for the quarter ending June 30, 2025 was $-40M, a 1100% decline year-over-year.
- Baxter change in accounts receivable for the twelve months ending June 30, 2025 was $-66M, a 146.15% decline year-over-year.
- Baxter annual change in accounts receivable for 2024 was $-0.035B, a 7.89% decline from 2023.
- Baxter annual change in accounts receivable for 2023 was $-0.038B, a 20.83% decline from 2022.
- Baxter annual change in accounts receivable for 2022 was $-0.048B, a 71.76% decline from 2021.
| Baxter Annual Change in Accounts Receivable (Millions of US $) |
|
|---|---|
| 2024 | $-35 |
| 2023 | $-38 |
| 2022 | $-48 |
| 2021 | $-170 |
| 2020 | $-119 |
| 2019 | $-52 |
| 2018 | $-12 |
| 2017 | $30 |
| 2016 | $15 |
| 2015 | $-4 |
| 2014 | $-93 |
| 2013 | $16 |
| 2012 | $-41 |
| 2011 | $-229 |
| 2010 | $-122 |
| 2009 | $-167 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $12.496B | $10.636B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.435B | 26.79 |
| Boston Scientific (BSX) | United States | $153.732B | 36.66 |
| Stryker (SYK) | United States | $149.077B | 30.35 |
| EssilorLuxottica (ESLOY) | France | $146.011B | 0.00 |
| Medtronic (MDT) | Ireland | $115.234B | 16.26 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.493B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.717B | 24.97 |
| ResMed (RMD) | United States | $41.881B | 29.95 |
| Agilent Technologies (A) | United States | $34.119B | 22.24 |
| GE HealthCare Technologies (GEHC) | United States | $33.772B | 15.87 |
| Terumo (TRUMY) | Japan | $27.820B | 32.97 |
| Koninklijke Philips (PHG) | Netherlands | $26.548B | 17.56 |
| Insulet (PODD) | United States | $23.052B | 77.24 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.663B | 13.15 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.153B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.804B | 28.67 |
| Lantheus Holdings (LNTH) | United States | $3.750B | 10.14 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.442B | 24.08 |
| Perrigo (PRGO) | Ireland | $3.247B | 8.11 |
| Prestige Consumer Healthcare (PBH) | United States | $3.219B | 14.28 |
| ICU Medical (ICUI) | United States | $3.055B | 20.80 |
| Haemonetics (HAE) | United States | $2.616B | 11.68 |
| LeMaitre Vascular (LMAT) | United States | $2.158B | 46.28 |
| QuidelOrtho (QDEL) | United States | $1.816B | 11.43 |
| AtriCure (ATRC) | United States | $1.781B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.676B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.566B | 67.25 |
| Phibro Animal Health (PAHC) | United States | $1.291B | 16.50 |
| AdaptHealth (AHCO) | United States | $1.279B | 18.17 |
| Neogen (NEOG) | United States | $1.219B | 19.34 |
| Acuren (TIC) | United States | $1.209B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.176B | 2454.00 |
| Tilray Brands (TLRY) | Canada | $1.167B | 0.00 |
| Valneva SE (VALN) | France | $0.975B | 0.00 |
| InMode (INMD) | Israel | $0.896B | 8.29 |
| Kestra Medical Technologies (KMTS) | United States | $0.805B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.639B | 0.00 |
| SNDL (SNDL) | Canada | $0.552B | 0.00 |
| ZimVie (ZIMV) | United States | $0.534B | 20.60 |
| Surmodics (SRDX) | United States | $0.534B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.506B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.501B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 16.10 |
| Evolus (EOLS) | United States | $0.461B | 0.00 |
| CeriBell (CBLL) | United States | $0.432B | 0.00 |
| Owens & Minor (OMI) | United States | $0.414B | 3.67 |
| Capricor Therapeutics (CAPR) | United States | $0.351B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.315B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.300B | 0.00 |
| Omeros (OMER) | United States | $0.297B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.275B | 0.00 |
| Brainsway (BWAY) | Israel | $0.273B | 55.65 |
| Viemed Healthcare (VMD) | United States | $0.270B | 20.44 |
| Aurora Cannabis (ACB) | Canada | $0.269B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.262B | 0.00 |
| High Tide (HITI) | Canada | $0.248B | 0.00 |
| Quanterix (QTRX) | United States | $0.234B | 0.00 |
| Cerus (CERS) | United States | $0.228B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.217B | 0.00 |
| Exagen (XGN) | United States | $0.212B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Organigram Global (OGI) | Canada | $0.204B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.187B | 15.61 |
| TriSalus Life Sciences (TLSI) | United States | $0.176B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.157B | 19.38 |
| Biote (BTMD) | United States | $0.149B | 4.95 |
| Jushi Holdings (JUSHF) | United States | $0.103B | 0.00 |
| Jin Medical (ZJYL) | China | $0.095B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.09 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.084B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Safety Shot (SHOT) | United States | $0.071B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.064B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.053B | 31.05 |
| Veru (VERU) | United States | $0.047B | 0.00 |
| Zynex (ZYXI) | United States | $0.047B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 34.42 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 13.98 |
| Trinity Biotech (TRIB) | Ireland | $0.025B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |